Novacea, Schering-Plough terminate Asentar trial

11/5/2007 | Yahoo!

Biotech drugmaker Novacea and its partner Schering-Plough have decided to end a Phase III trial of prostate cancer drug Asentar. Researchers found that a trial group of prostate-cancer patients taking Asentar with Sanofi-Aventis' cancer drug Taxotere had a higher death rate compared to the group undergoing standard treatment.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC